Table 2.

Adverse events, discontinuation rate, and number of patients at each timepoint (week 16, week 28, week 52, week 88, week 104).

Baseline: patients, n (%)	168 (100)
Week 16: patients, n (%)	168 (100.0)
Weeks 28: patients, n (%)	152 (90.5)
Week 52: patients, n (%)	118 (70.2)
Week 88: patients, n (%)	98 (58.3)
Week 104: patients, n (%)	76 (45.2)
Discontinuation rate for inefficacy, n (%)	15 (8.9)
Adverse events, n (%)	48 (28.6)
Pharyngitis	20 (11.9)
Flu-like illness	13 (7.7)
Headache	12 (7.1)
Diarrhea	8 (4.8)
Others	5 (3.0)